OrbiMed

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

2 Sept 2025

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

Charm Therapeutics develops next generation cancer drugs designed to overcome treatment resistance, using an AI driven discovery platform to identify compounds for aggressive blood cancers such as AML.

OrbiMed

- Life Sciences
1(12 months)
orbimed.com
Update Information

More venture news

Greyparrot
29 Jul 2026
Greyparrot raises £20m Series B from angels for AI camera systems that read waste on recycling belts
Series BClimate
Qureight
29 Jul 2026
Qureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Series BLife Sciences
28 Jul 2026
Dwelly lands £130m in funding led by EQT Growth and General Catalyst to acquire and run independent lettings agencies on shared AI infra
Series BProperty

OrbiMed

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

More venture news

Greyparrot raises £20m Series B from angels for AI camera systems that read waste on recycling belts

Qureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease

Dwelly lands £130m in funding led by EQT Growth and General Catalyst to acquire and run independent lettings agencies on shared AI infra